AJP - Heart and Circulatory Physiology, Vol 270, Issue 6 1924-H1932, Copyright © 1996 by American Physiological Society

ARTICLES

Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences

P. F. Lennon, C. D. Collard, M. A. Morrissey and G. L. Stahl
Department of Anesthesia, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Activation of complement and attenuation of endothelium-dependent relaxation occur in a number of pathophysiological conditions. The aim of this study was to investigate the mechanisms of human complement activation and loss of endothelium-dependent relaxation in rabbit tissue, the duration of this loss, and the effects of gender and serum concentration. In rabbit thoracic aortic rings precontracted with phenylephrine, human serum (HS) concentration dependently induced a loss of endothelium-dependent relaxation to the receptor-dependent vasodilator acetylcholine (ACh) and receptor-independent vasodilator calcium ionophore A23187. Serum-induced loss of ACh-dependent relaxation was decreased when rings were bathed in 1) HS depleted of factor B, C2, or C8, 2) heat-inactivated HS, or 3) HS with complement inhibitor sCR1 or sCR1[desLHR-A]. Superoxide dismutase had no effect on serum-induced loss of ACh-dependent relaxation. Serum-induced loss of ACh-dependent relaxation returned to control values after removal of HS. Serum-induced loss of ACh-dependent relaxation was greater in male than in female aortic rings. These results suggest that 1) complement activation directly attenuates endothelium-dependent relaxation via the classical and alternative pathways independent of superoxide anion formation, 2) this attenuation is concentration dependent, reversible, and dependent on formation of C5b-9, and 3) endothelial tissue from males is more susceptible than that from females to the acute effects of complement activation.

This article has been cited by other articles:

				R. Lekowski, C. D. Collard, W. R. Reenstra, and G. L. Stahl Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation Protein Sci., February 1, 2001; 10(2): 277 - 284. [Abstract] [Full Text]

				A. Agah, M. C. Montalto, C. L. Kiesecker, M. Morrissey, M. Grover, K. L. Whoolery, R. P. Rother, and G. L. Stahl Isolation, Characterization, and Cloning of Porcine Complement Component C7 J. Immunol., July 15, 2000; 165(2): 1059 - 1065. [Abstract] [Full Text] [PDF]

				C. D. Collard, A. Vakeva, M. A. Morrissey, A. Agah, S. A. Rollins, W. R. Reenstra, J. A. Buras, S. Meri, and G. L. Stahl Complement Activation after Oxidative Stress : Role of the Lectin Complement Pathway Am. J. Pathol., May 1, 2000; 156(5): 1549 - 1556. [Abstract] [Full Text] [PDF]

				E. N. T. P. Bakker, E. T. van der Meulen, J. A. E. Spaan, and E. VanBavel Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1233 - H1240. [Abstract] [Full Text] [PDF]

				C. D. Collard, A. Agah, W. Reenstra, J. Buras, and G. L. Stahl Endothelial Nuclear Factor-{kappa}B Translocation and Vascular Cell Adhesion Molecule-1 Induction by Complement : Inhibition With Anti-Human C5 Therapy or cGMP Analogues Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2623 - 2629. [Abstract] [Full Text] [PDF]

				C. W. Rittershaus, L. J. Thomas, D. P. Miller, M. D. Picard, K. M. Geoghegan-Barek, S. M. Scesney, L. D. Henry, A. C. Sen, A. M. Bertino, G. Hannig, et al. Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules J. Biol. Chem., April 16, 1999; 274(16): 11237 - 11244. [Abstract] [Full Text] [PDF]

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]